母亲产前维生素使用与孤独症谱系障碍复发风险的关联
本研究基于MARBLES前瞻性队列,分析241名孤独症谱系障碍(ASD)患儿的高危弟妹,发现母亲在妊娠第一个月使用产前维生素与子代ASD复发风险降低相关(调整RR 0.50;95%CI 0.30-0.81),且ASD症状严重度更低、认知评分更高。
要点
- 高危家庭中,母亲妊娠首月使用产前维生素与子代ASD复发风险降低相关。
- 该关联未见于非典型发育这一36月龄结局(调整RR 1.14;95%CI 0.75-1.75)。
- 产前维生素组ASD症状严重度更低、认知评分更高,需进一步研究确认。
核心结论
- 母亲妊娠第一个月使用产前维生素可能降低高危家庭中ASD患儿弟妹的ASD复发风险。
- 该关联需更多研究确认,并需探究剂量阈值、相关营养素与生物学机制。
研究设计与样本
- 前瞻性队列研究,分析MARBLES研究中332名儿童与305名母亲的数据。
主要发现
- 最终样本241名弟妹中男性140名(58.1%)、女性101名(41.9%),平均(SD)年龄36.5(1.6)个月。
- 231名母亲(95.9%)报告孕期使用产前维生素,仅87名(36.1%)符合孕前6个月服用的建议。
- 母亲妊娠第一个月使用产前维生素者子代ASD患病率为14.1%(18例),未使用者为32.7%(37例)。
- 妊娠第一个月使用产前维生素与ASD诊断风险降低相关(调整RR 0.50;95%CI 0.30-0.81),与非典型发育36月龄结局无关(调整RR 1.14;95%CI 0.75-1.75)。
- 产前维生素组ASD症状严重度更低(调整估计差值-0.60;95%CI -0.97至-0.23),认知评分更高(调整估计差值7.1;95%CI 1.2-13.1)。
关键数值与推荐
- ASD、其他非典型发育(non-TD)与典型发育(TD)依据ADOS与Mullen Scales of Early Learning分量表得分算法化定义。
- 调整RR 0.50(95%CI 0.30-0.81)对应妊娠第一个月使用产前维生素与子代ASD诊断的关联。
临床怎么用
- 对ASD患儿家庭再生育咨询时,可告知妊娠早期使用产前维生素与子代ASD复发风险降低相关,但证据尚需确认。
- 不建议据此改变现有产前维生素公共卫生建议,需等待剂量阈值与机制研究结果。
局限性
- 产前维生素使用为母亲电话访谈自我报告,可能存在回忆偏倚。
- 样本来自加州主要为接受ASD服务的家庭,外推性受限。
- 作者指出需更多研究确认结果并探究剂量阈值、相关营养素与生物学机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Maternal use of folic acid supplements has been inconsistently associated with reduced risk for autism spectrum disorder (ASD) in the child. No study to date has examined this association in the context of ASD recurrence in high-risk families. OBJECTIVE: To examine the association between maternal prenatal vitamin use and ASD recurrence risk in younger siblings of children with ASD. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study analyzed data from a sample of children (n = 332) and their mothers (n = 305) enrolled in the MARBLES (Markers of Autism Risk in Babies: Learning Early Signs) study. Participants in the MARBLES study were recruited at the MIND Institute of the University of California, Davis and were primarily from families receiving services for children with ASD in the California Department of Developmental Services. In this sample, the younger siblings at high risk for ASD were born between December 1, 2006, and June 30, 2015, and completed a final clinical assessment within 6 months of their third birthday. Prenatal vitamin use during pregnancy was reported by mothers during telephone interviews. Data analysis for this study was conducted from January 1, 2017, to December 3, 2018. MAIN OUTCOMES AND MEASURES: Autism spectrum disorder, other nontypical development (non-TD), and typical development (TD) were algorithmically defined according to Autism Diagnostic Observation Schedule and Mullen Scales of Early Learning subscale scores. RESULTS: After exclusions, the final sample comprised 241 younger siblings, of which 140 (58.1%) were male and 101 (41.9%) were female, with a mean (SD) age of 36.5 (1.6) months. Most mothers (231 [95.9%]) reported taking prenatal vitamins during pregnancy, but only 87 mothers (36.1%) met the recommendations to take prenatal vitamins in the 6 months before pregnancy. The prevalence of ASD was 14.1% (18) in children whose mothers took prenatal vitamins in the first month of pregnancy compared with 32.7% (37) in children whose mothers did not take prenatal vitamins during that time. Children whose mothers reported taking prenatal vitamins during the first month of pregnancy were less likely to receive an ASD diagnosis (adjusted relative risk [RR], 0.50; 95% CI, 0.30-0.81) but not a non-TD 36-month outcome (adjusted RR, 1.14; 95% CI, 0.75-1.75) compared with children whose mothers reported not taking prenatal vitamins. Children in the former maternal prenatal vitamin group also had statistically significantly lower autism symptom severity (adjusted estimated difference, -0.60; 95% CI, -0.97 to -0.23) and higher cognitive scores (adjusted estimated difference, 7.1; 95% CI, 1.2-13.1). CONCLUSIONS AND RELEVANCE: Maternal prenatal vitamin intake during the first month of pregnancy may reduce ASD recurrence in siblings of children with ASD in high-risk families. Additional research is needed to confirm these results; to investigate dose thresholds, contributing nutrients, and biologic mechanisms of prenatal vitamins; and to inform public health recommendations for ASD prevention in affected families.
引用
- Schmidt RJ, Iosif AM, Guerrero Angel E, et al. Association of Maternal Prenatal Vitamin Use With Risk for Autism Spectrum Disorder Recurrence in Young Siblings. JAMA Psychiatry. 2019. PMID: 30810722. doi:10.1001/jamapsychiatry.2018.3901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。